Scientists test double hunger blocker for obesity

NCT ID NCT07171723

Recruiting now Knowledge-focused Sponsor: University Hospital, Gentofte, Copenhagen Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how the body's hunger signals work when a person is already taking a medication like semaglutide for weight loss. Researchers will give 24 participants with obesity an infusion that temporarily blocks a key hunger hormone (ghrelin) or a placebo, while they continue their regular semaglutide treatment. The goal is to see if blocking this second hunger pathway further affects food intake and metabolism, which could inform future combination treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY &AMP; OVERWEIGHT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Center for Clinical Metabolic Research, Gentofte Hospital
RECRUITING

Hellerup, 2900, Denmark

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

OBESITY &AMP; OVERWEIGHT